Base to Base biotech podcast 43: Natural killer cell therapy and attacking tumours

Base to Base Biotech di Jim Cornall

Note sull'episodio

This week, we have a conversation with Lisa Guerrettaz, executive director, Pharmacology and Translational Science at Artiva Biotherapeutics; and Avacta Therapeutics’ CEO Christina Coughlin.

Times:

04:12 Artiva Biotherapeutics

21:30 Avacta Therapeutics

Artiva Biotherapeutics

Artiva Biotherapeutics is a clinical‑stage cell therapy company developing off‑the‑shelf (allogeneic) natural killer (NK) cell therapies for autoimmune diseases and cancer. Headquartered in San Diego and founded in 2019, the company was created as a spin‑out from GC Cell (formerly GC Lab Cell) in South Korea, alongside a strategic partnership granting Artiva exclusive rights (outsid ... 

 ...  Leggi dettagli
Parole chiave
biotechbiotechnologycancernk cellsAvacta TherapeuticsArtiva Biotherapeutics